FDA to review Xolair sBLA for chronic idiopathic urticaria

FDA accepted for review an sBLA from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) to expand the label of Xolair omalizumab to include chronic idiopathic urticaria (CIU). The PDUFA date is i...